Skip to main content

Table 1 Patient baseline characteristics and clinical presentations compared between groups

From: Long-term outcome of percutaneous transluminal renal angioplasty (PTRA) versus PTRA with stenting (PTRAS) in transplant renal artery stenosis

Baseline characteristics and clinical presentations

Overall (n = 65)

PTRA (n = 34)

PTRAS (n = 31)

p value

Age, years

42.5 ± 11.9

42.8 ± 12.4

42.1 ± 11.5

0.817

Male gender

40 (61.5%)

21 (61.8%)

19 (61.3%)

0.969

Right ABI

1.16 (1.02, 1.28)

1.17 (1.17, 1.17)

1.15 (1.02, 1.28)

0.789

Left ABI

1.12 (0.93, 1.33)

1.17 (1.17, 1.17)

1.12 (0.93, 1.33)

0.687

ESRD etiology

    

 DM

7 (10.8%)

5 (14.7%)

2 (6.5%)

0.566

 HT

3 (4.6%)

1 (2.9%)

2 (6.5%)

 

 PKD

2 (3.1%)

2 (5.9%)

0 (0.0%)

 

 GN

29 (44.6%)

14 (41.2%)

15 (48.4%)

 

 Other

24 (36.9%)

12 (35.3%)

12 (38.7%)

 

Donor type

    

 Living

23 (35.4%)

11 (32.4%)

12 (38.7%)

0.592

 Deceased

42 (64.6%)

23 (67.6%)

19 (61.3%)

19 (61.3%)

 

TRAS symptomatology

    

 Uncontrolled HT

11 (16.9%)

6 (17.6%)

5 (16.1%)

0.987

  Worsening renal function

38 (58.5%)

20 (58.8%)

18 (58.1%)

 

 Uncontrolled HT and worsening renal

11 (16.9%)

5 (14.7%)

6 (19.4%)

 

 Worsening and Pulmonary edema

1 (1.5%)

1 (2.9%)

0 (0.0%)

 

 Other

4 (6.2%)

2 (5.9%)

2 (5.9%)

2 (6.5%)

 
  1. Data presented as number and percentage, median (minimum,maximum), or mean ± standard deviation
  2. PTRA, percutaneous transluminal renal angioplasty; PTRAS, percutaneous transluminal renal angioplasty with stenting; ABI, ankle brachial index; ESRD, end-stage renal disease; DM, diabetes mellitus; HT, hypertension; PKD, polycystic kidney disease; GN, glomerulonephritis
  3. A p-value < 0.05 indicates statistical significance